ITGR · Integer Holdings Corporation · Stock research

Current Thesis

Since 2026-08-03 this has been a signed-deal instrument. KKR's affiliate agreed to acquire Integer for $127.00 per share in cash, an enterprise value of approximately $5.7B, with the board unanimously recommending the transaction. The last completed daily close was $125.27 (2026-08-07); the gap to the stated consideration is $1.73, roughly 1.4% of that close. The narrative an investor would be buying is no longer medical-device contract manufacturing — it is completion odds on a fully committed, no-financing-condition take-private guided to close by year-end 2026 against an outside date of 2027-05-02. Everything above $127 requires a competing bid that does not currently exist.

Bullish and bearish views on Integer Holdings Corporation

The model's bull view on Integer Holdings Corporation (ITGR), in brief: Definitive agreement, not a proposal (2026-08-03): all-cash $127, EV ~$5.7B, equity from KKR-managed funds plus committed debt. The bear view: Upside is contractually capped. At $125.27 (2026-08-07) the remaining headline consideration is $1.73. There is no fundamental path above $127 while this agreement stands. Sell-side has already collapsed onto the deal price. KeyBanc to Sector Weight (2026-08-03); Oppenheimer to… Both cases follow in full.

Bull Case

• Definitive agreement, not a proposal (2026-08-03): all-cash $127, EV ~$5.7B, equity from KKR-managed funds plus committed debt. No financing contingency. Lead arrangers named in the announcement: Citi, KKR Capital Markets, Barclays, UBS, Jefferies.
• Fee asymmetry favors the seller: parent reverse termination fee $307M versus a $154M company fee, per the merger-agreement terms filed with the 2026-08-03 8-K. The $154M company fee sits against a ~$5.7B EV, which is not a prohibitive toll on a topping bid.
• The Q2 print landed the same day and beat: sales $464.110M vs $450.505M consensus; adjusted EPS $1.60 vs $1.42 consensus (2026-08-03). A quarter that clears expectations into signing weakens any later material-adverse-effect argument.
• Financial-sponsor buyer: KKR carries no medical-device manufacturing overlap with Integer, so the horizontal-overlap path to an antitrust problem is narrower than in a strategic combination. This is an inference from the buyer's identity, not a disclosed regulatory position.
• Runway: the 2027-05-02 outside date leaves roughly nine months against a year-end 2026 closing guide — slack for a second request or a slow proxy without the agreement lapsing.
• Premium is already banked: $127 was disclosed as a 51.8% premium to the 2026-04-29 close and 28.8% to the 30-day VWAP through 2026-07-31.

Bear Case

• Upside is contractually capped. At $125.27 (2026-08-07) the remaining headline consideration is $1.73. There is no fundamental path above $127 while this agreement stands.
• Sell-side has already collapsed onto the deal price. KeyBanc to Sector Weight (2026-08-03); Oppenheimer to Perform (2026-08-04); Truist to Hold with PT $127; Wells Fargo Equal-Weight with PT $127 (both 2026-08-04). Four houses neutralized inside 48 hours and two targets set precisely at the consideration.
• The un-deal anchors are far below. Pre-leak marks: Citi Neutral PT $96 (2026-07-08), Truist Buy PT $110 (2026-07-16). A break returns the equity toward that zone, roughly 12–24% below the 2026-08-07 close.
• The standalone business is shrinking. Q2 2026 sales fell 2.6% YoY, organic sales -1.5%. Integer withdrew its previously issued FY2026 outlook on 2026-08-03 because of the pending transaction, so no company forecast exists to underwrite a break price.
• Funding still has to clear. No financing condition is a contractual protection, not a market one; a ~$5.7B EV LBO syndication remains exposed to credit conditions between signing and funding.
• RSI(14) 95.6 and a +42.2% three-month return through 2026-08-07 are step-function artifacts of the 2026-07-31 leak and the 2026-08-03 signing. Those readings will pull momentum and breakout screens toward a security whose contractual upside is $1.73.

Setup & Price Structure

• 2026-07-31: WSJ reported KKR near a deal at roughly $127. Shares were halted on an upside circuit breaker with the stock up 11.05%, then resumed the same session.
• 2026-08-03: definitive agreement plus Q2 results. The gap between the pre-leak trading range and $127 closed in two sessions.
• 2026-08-07: close $125.27; 52-week high $126.07, i.e. 0.6% below the high. The 52-week high itself sits $0.93 under the cash consideration.
• Structure now: post-announcement pinning. Price action is a narrow band beneath $127, and the distribution is bimodal — closing at $127 or breaking toward the pre-leak analyst zone. Conventional trend geometry (rising moving averages, breakout shelves) carries no information about a price fixed by contract.
• Life-cycle: SATURATED. Dated by the 2026-08-03/2026-08-04 downgrade cluster, by two price targets set at exactly the deal price, and by a share price parked within 0.6% of a 52-week high that is capped above by the merger agreement. Mainstream coverage is complete and there is no incremental fundamental bid.
• What would flip it back to ACCELERATING: a superior proposal or an amended price above $127. Absent that, the only remaining variable is time-to-close.
• Positioning observables: four analyst rating changes to neutral within 48 hours of announcement; two targets pinned at $127; RSI(14) 95.6; no insider Form 4 activity in the filing record reviewed as of 2026-08-08. Under the merger agreement, unvested RSU/PSU awards are 50% cashed out at closing with 50% remaining subject to existing service vesting — management's remaining economics are tied to the deal completing rather than to the tape.

Catalyst Calendar (next 30 days)

• ~2026-09-02 (est.) — preliminary merger proxy (PREM14A). Not filed as of 2026-08-08. It sets the special-meeting date and discloses the background of the merger, the financial analysis, and the full deal-protection package.
• ~2026-09-15 (est.) — expiry of the HSR initial 30-day waiting period. The filing date has not been disclosed, so this window is an estimate; a second request rather than expiry is the observable that matters.
• 2026-12-31 — the company's stated closing target ("by the end of the year," 2026-08-03 announcement). No confirmed hard-dated catalyst falls inside the next 30 days.
• 2027-05-02 — outside date under the merger agreement. Beyond the 30-day window but the binding constraint on the timeline.

What Would Change Our Mind

The thesis breaks the moment the spread stops behaving like a funded deal's. A fully committed, no-financing-condition agreement with a $307M reverse fee normally trades within a point or two of consideration; persistent widening means the market is re-underwriting completion odds rather than discounting time. Concretely: a daily close below $118 — a discount of more than 7% to the $127 cash consideration — is the gradeable break.

Secondary conditions that would independently change the read:

• An 8-K disclosing an HSR second request, or a proxy that guides closing into H1 2027 rather than year-end 2026 — both stretch the holding period without improving the payoff.
• The 2026-12-31 closing guide passing without a completed transaction and without a stated new target date.
• On the other side: any disclosed superior proposal above $127 would reopen upside and move the life-cycle label off SATURATED.
• A DEFA14A disclosing that a proxy advisor recommends against the merger, or litigation that adjourns the special meeting.

Correlation Notes

• Since the 2026-08-03 signing, the driver set is deal completion rather than orthopedic/cardio end-market demand. Correlation to medtech peers and to broad healthcare beta should decay toward zero while the agreement stands; this is an inference from deal mechanics, and the observable that confirms it is price remaining pinned in a narrow band under $127 through peer-group moves.
• The relevant correlated cohort is other pending sponsor take-privates and the leveraged loan / high-yield market, because funding for a ~$5.7B EV LBO clears through it. A financing shock at one large sponsor deal historically widens spreads across the cohort at the same time.
• The Q2 2026 fundamental data (sales -2.6% YoY, organic -1.5%, 2026-08-03) matters only conditionally: it is irrelevant to a completing deal and is the valuation anchor if the deal breaks, alongside the pre-leak targets of $96 (Citi, 2026-07-08) and $110 (Truist, 2026-07-16).
• Withdrawn FY2026 guidance removes the usual quarterly re-rating mechanism, so the security will not respond to sector estimate revisions the way it did before 2026-07-31.